首页> 外文期刊>The Journal of Urology >Radical retropubic prostatectomy in immunosuppressed transplant recipients.
【24h】

Radical retropubic prostatectomy in immunosuppressed transplant recipients.

机译:免疫抑制的移植受者根治性耻骨后前列腺切除术。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: Surgical treatment of transplant recipients in whom prostate cancer subsequently develops has been reported only sporadically in the literature. We reviewed our experience with radical retropubic prostatectomy in patients with solid organ transplants. MATERIALS AND METHODS: Using our prostatectomy registry we identified 17 patients who underwent radical retropubic prostatectomy between 1988 and 2005 following organ transplantation. Clinicopathological features and outcome data were reviewed. RESULTS: Kidney, liver and heart transplants were performed before radical retropubic prostatectomy in 9, 7 and 3 patients, respectively. Median age at transplant and time of radical retropubic prostatectomy was 51 (range 37 to 65) and 59 years (range 45 to 70), respectively. Median prostate specific antigen was 5.8 (range 2.6 to 12.9) and all patients had clinically localized disease. Ten patients had a pathological Gleason score of 6 while the remaining had Gleason scores 7 or greater. No patient had positive lymph nodes and only 2 patients had pT3a or greater disease. Early complications included wound infection in 2 (12%) patients along with hematoma and myocardial infarction in 1 (6%) patient each. Late complications included incontinence (1 or more pads per day) in 2 patients while no patient had a hernia, bladder neck contracture, venous thrombosis or lymphocele. With a median followup of 4.9 years, biochemical recurrence developed in 1 patient and no patient had systemic progression or death due to prostate cancer. CONCLUSIONS: To our knowledge we report the largest experience with radical retropubic prostatectomy in transplant recipients. Our results suggest that radical retropubic prostatectomy is feasible for immunosuppressed patients, yet concern for infection and wound healing remain important. Healthy transplant recipients with an increased prostate specific antigen should undergo a prostate biopsy.
机译:目的:外科治疗在随后发展为前列腺癌的移植受者中的报道只是零星的。我们回顾了我们在实体器官移植患者中进行耻骨后前列腺癌根治术的经验。材料与方法:使用我们的前列腺切除术登记系统,我们确定了在器官移植后的1988年至2005年之间接受根治性耻骨后前列腺切除术的17例患者。回顾了临床病理特征和结果数据。结果:分别在9、7和3例根治性耻骨后前列腺切除术前进行了肾脏,肝脏和心脏移植手术。移植时的中位年龄和根治性耻骨后前列腺切除术的中位年龄分别为51岁(37至65岁)和59岁(45至70岁)。前列腺特异性抗原的中位数为5.8(范围从2.6到12.9),所有患者均患有临床局部疾病。十名患者的病理学Gleason评分为6,而其余患者的Gleason评分为7或更高。没有患者的淋巴结阳性,只有2名患者患有pT3a或更大的疾病。早期并发症包括2(12%)位患者的伤口感染以及1(6%)位患者的血肿和心肌梗塞。晚期并发症包括2例患者的失禁(每天1个或更多垫子),而没有患者出现疝气,膀胱颈挛缩,静脉血栓形成或淋巴膨出。中位随访时间为4.9年,1名患者发生了生化复发,没有患者因前列腺癌而出现全身性进展或死亡。结论:据我们所知,我们报告了在移植受者中进行耻骨后前列腺癌根治术的最大经验。我们的结果表明,根治性耻骨后前列腺切除术对于免疫抑制的患者是可行的,但是对感染和伤口愈合的关注仍然很重要。前列腺特异性抗原增加的健康移植受者应进行前列腺活检。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号